Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (Nasdaq: MNKD) has appointed Lauren Sabella as Executive Vice President and Chief Operating Officer effective March 27, 2023. Reporting directly to CEO Michael Castagna, Sabella brings over 12 years of experience from Acorda Therapeutics, where she served as COO. Her previous roles include Chief Commercial Officer and Vice President of Commercial Development, contributing to significant product launches with peak sales exceeding $1 billion. Sabella will oversee critical operations in Danbury, focusing on expanding MannKind's endocrine business and preparing to launch new products in the orphan lung disease market.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
